Location History:
- Morphett Vale, AU (2013)
- Woodville West, AU (2016 - 2018)
Company Filing History:
3 out of 64 
2 out of 2,945 
Years Active: 2013-2018
Title: Rachel Christine Cooke: Innovator in Potassium Channel Modulation
Introduction
Rachel Christine Cooke is a prominent inventor based in Morphett Vale, Australia. She has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate potassium channel activity. With a total of 3 patents to her name, Cooke's work has the potential to impact the treatment of various autoimmune and inflammatory diseases.
Latest Patents
One of her latest patents focuses on amine derivatives as potassium channel blockers. This invention relates to compounds that are useful in modulating potassium channel activity in cells, specifically targeting the Kv1.3 channels found in T cells. The invention also encompasses the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis. Additionally, it includes pharmaceutical compositions containing these compounds and methods for their preparation.
Career Highlights
Throughout her career, Rachel has worked with notable companies such as Bionomics Inc. and Merck Patent GmbH. Her experience in these organizations has allowed her to refine her expertise in drug development and patenting innovative solutions for complex medical challenges.
Collaborations
Rachel has collaborated with esteemed colleagues, including Andrew John Harvey and Nathan Wayne Kuchel. These partnerships have further enriched her research and development efforts, leading to advancements in her field.
Conclusion
Rachel Christine Cooke is a trailblazer in the realm of potassium channel modulation, with a focus on developing therapeutic solutions for autoimmune and inflammatory diseases. Her innovative patents and collaborations highlight her commitment to advancing medical science.